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Recent advances in clinical anti-cancer  
immunotherapy
Abstract
Recent successful results with the relatively novel immunotherapeutic 
anti-cancer strategies such as adoptive T cell transfer (ACT), engineered T 
cells with chimeric antigen receptors (CARs), therapeutic Sipuleucil-T vac-
cine and checkpoint blockade inhibitors, do indicate that patient’s immune 
system can be effectively used against autologous tumor cells. Interactions 
between the immune system and the malignancy are complex but the results 
obtained using the above mentioned therapeutic approaches indicate accept-
able clinical utility, efficacy and safety against several types of cancer. Much 
work still lies ahead but the success achieved with these modern immuno-
therapies is undeniable. This paper aims to present a short basic overview of 
these recent advances in cancer immunotherapy, but one should keep in 
mind that this field is in a dynamic stage given its success and that many 




The established clinical therapeutic modalities for cancer treatment are surgery, cytotoxic chemotherapy and radiotherapy applied either 
alone or in combinations depending on the tumor type, tumor stage, 
patient’s general condition and functional organ reserves. The treatment 
intention may be curative or the palliative. Newer molecularly targeted 
drugs and biologic agents have shown activity in some cancers refrac-
tory to traditional chemotherapeutics, but in some tumor types they too 
do not appear to be as effective as initially thought. Besides the primary 
goal of having an effective anti-cancer therapy, the side effects ranging 
from tolerable ones to sometimes even fatal ones should also always be 
taken into account in therapy planning. Moreover, the price of such 
newer drugs and treatments compared to their effectiveness is becoming 
more and more relevant, especially where the cure or long term tumor 
control is not predictable or expected. The monthly prices of newer drugs 
can be up to several tens of thousands of dollars or euros, raising the 
question of cost-effectiveness (1–3).
The idea to use the immune system effector mechanisms against 
autologous tumor cells is an attractive idea, partly based on the proven 
effectiveness (body protection), specificity and tolerable side effects ob-
tained with vaccines against a variety of infectious pathogens. This idea 
that an immune system can also be used against autologous tumor cells, 
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i.e. to recognize autologous tumor cells as body-foreign 
cells can be traced back more than 100 years to the past. 
For example, in works and publications by William B. 
Coley (“Coley’s Toxin”) and by Paul Ehrlich. Later, for 
example, an idea of cancer “immunosurveillance” was 
proposed by Macfarlane Burmet and Lewis Thomas more 
than 50 years ago, where the immune system should have 
a homeostatic role in controlling cancer. When onco-
genic or other mutations occurred, the immune system 
was, in theory, thought to recognize the encoded mutated 
proteins and respond, thereby preventing the develop-
ment of a tumor, at least when the system was operating 
normally (1, 4–9).
Later experimental evidence, mainly from murine tu-
mor models in the second half of the 20th century, sup-
ported this idea of the immune system-based possibility 
of cancer cell elimination. It was demonstrated that the 
immune response against cancer involves different effec-
tor mechanisms of adaptive and innate immunity, with 
the predominant role of cytotoxic CD8+ T cells (CTLs), 
but it may also include antibodies, natural killer (NK) 
cells and granulocytes and macrophages. Despite very ef-
fective and curative anti-tumor responses obtained in 
various experimental animal models, in daily clinical 
practice these various immune-based approaches were 
until recently of limited effectives and consequently of 
limited clinical applicability. Various mechanisms rang-
ing, for example, from low immunogenicity and low ex-
pression of potential tumor antigens on tumor cells, their 
downregulation, presence of various soluble immunosup-
pressive factors and/or cell-bound molecules on regula-
tory (suppressor) immune cells or on tumor cells within 
the tumor microenvironment may have an adverse effect 
on the afferent and the efferent phases of the immune 
anti-tumor response. Due to their similarity to normal 
cells, cancer cells have in fact many ways of evading and 
thus escaping an otherwise possible effective immune re-
sponse against microorganisms and against allogeneic cell 
transplants. It seems that tumor-related antigens may not 
be properly presented, antigens may be recognized as 
“self” and may induce anergy, T-lymphocytes may not be 
appropriately activated, or T-lymphocytes may be exces-
sively inhibited (1, 2, 9–16).
In the past 10 to 15 years, several immunotherapeutic 
approaches have been shown to have promising clinical 
impact. In addition to the relatively high price, for some 
of these approaches, although with promising results, 
there may be a practical problem in the routine applicabil-
ity in a daily busy clinical setting. These newer immuno-
therapeutic approaches include several variations of the 
adoptive T cell transfer therapy (17–22); vaccines (2, 
23, 24) such as the first therapeutic cellular vaccine ap-
proved by the United States Food and Drug Administra-
tion (FDA), Sipuleucel-T (25); and checkpoint blockade 
inhibitors, such as the FDA-approved anti-CTLA4 an-
tibody (mab) (ipilimumab) (26, 27) and the anti-PD-
1:PD-1 ligand mabs (28–32).
The antitumor responses obtained with the vaccine 
and checkpoint immune modulators may be time-delayed 
and mixed (lesions may enlarge before shrinking, lesions 
may remain stable or slowly regress over time). These type 
of tumor response dynamics can be explained by the time 
required for the T-cell activation in vivo, tumor infiltra-
tion, antigen modulations on target (tumor) cells, as well 
as by intra-patient heterogeneity of tumor–host interac-
tions. Also, since an anti-tumor response is usually ob-
tained in only a subset of patients, this also results in 
ongoing studies aiming to identify the response predictors 
(biomarkers) (33–36).
ADOpTIve T-Cell TRANsfeR
Adoptive T cell transfer (ACT) immunotherapy em-
ploys the reinfusion of large numbers of autologous T cells 
previously expanded and activated in vitro (ex vivo) with 
high avidity for tumor antigens or cells. The source of 
tumor-specific T cells is either naturally-occurring au-
tologous T cells from the tumor microenvironment (e.g., 
tumor-infiltrating lymphocytes, TILs) or blood or ge-
netically engineered T cells expressing high affinity tu-
mor-specific T cell receptors (TCRs). These cells are ex-
panded in vitro in the presence of various growth factors 
and infused to patients after they normally receive a pre-
parative lymphodepleting regimen. To enhance T-cell 
activation, interleukin-2 (IL-2) might be used. Using these 
approaches, objective responses reaching 50% with last-
ing remissions have been achieved in patients with meta-
static melanoma treated with autologous TILs (17–22).
The main problems or limitations in the clinical devel-
opment and application of ACT pertain to the time re-
quired together with the labor-intensive methods and the 
use of sophisticated technologies to develop and grow 
specific T cell clones or T cell lines in vitro in a sufficient 
number, their short half-life after transfer into the patient 
and the need for an individual development of T cells due 
to HLA-restriction. The in vivo half-life of the transferred 
T cells could be increased after lymphodepletion of re-
cipients before adoptive transfer.
Advances in T cell engineering using lentiviral and 
retroviral vectors carrying genetically engineered TCRs 
expanded the opportunities for ACT. Recombinant vi-
ruses encoding either conventional αβT‑cell receptors 
(TCR) or chimeric antigen receptors (CARs) are ca-
pable of inserting genes into the genome of human lym-
phocytes with efficiencies exceeding 80%. CARs are 
chimeric single-chain constructs composed of antibody-
derived complementarity-determining region fused to a 
T-cell receptor (TCR) signaling domain. Genetic transfer 
of CAR genes to autologous T cells results in T cells that 
are activated and proliferated in vivo upon contact with 
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their antigen. The advent of CARs bypasses the need for 
tumor cells to possess functional antigen-processing ma-
chinery and express antigen through MHC class I or II 
molecules; transduced T cells are able to recognize the 
intact surface protein through the artificial CAR. Clini-
cally, this may lead to both lysis of a large tumor burden 
and development of immunologic memory for that spe-
cific target antigen. Preclinical and clinical evaluations 
have resulted in stepwise improvements in the constructs 
used to produce CARs. Genetically engineered T cells 
were shown to recognize and destroy hematopoietic tu-
mor cells, particularly those involving anti-CD19-based 
CARs for the treatment of B-cell malignancies or some 
solid tumors expressing the cognate antigens. The CARs 
approach combines elements of genetic engineering and 
molecular biology to create new biological structures with 
enhanced functionalities. CAR therapy, as it currently 
exists, requires consequently a multidisciplinary team 
composed of devoted molecular biologists, immunologists 
and clinicians within a hospital environment, so at present 
time it is in practice in several high-quality and high-
ranking academic institutions, predominantly in the 
USA. Clinical trials have already shown clinically sig-
nificant antitumor activity in chronic lymphocytic leuke-
mia, B cell lymphoma, neuroblastoma. Trials targeting a 
variety of other adult and pediatric malignancies are also 
under way. The clinical responses to the ACT transfer are 
most often observed in days to weeks, in contrast to usu-
ally much slower time-response to tumor vaccines and 
checkpoint blockade. Reported toxicities such as fever, 
hypotension and metabolic complications can be related 
to the elevated proinflamatory serum cytokine levels and 
to the systemic release of various intracellular molecules 
due to the tumor cells lysis and in depletion of normal B 
cells in case of anti-CD19-based CARs application (17–
22).
vACCINATION
Sipuleucel-T (Provenge) is to date the only therapeu-
tic anti-cancer vaccine that has been licensed for use in 
clinical practice. It was first licensed by the U.S. Food and 
Drug Administration (FDA) in 2010 for use in the treat-
ment of asymptomatic/minimally symptomatic meta-
static castration-resistant prostate cancer (mCRPC) (25). 
It involves an autologous cell transplant, whereby periph-
eral blood mononuclear cells (PBMCs) in a sufficient 
number are taken from the patient using the leukapher-
esis procedure and incubated with a fusion protein con-
sisting of recombinant prostate acid phosphatase (PAP; a 
tumor associated antigen expressed in prostate tumor 
cells) and granulocyte-macrophage colony stimulating 
factor (GM-CSF). Dendritic cells in the PBMC sample 
should take up PAP and express it as part of a major his-
tocompatibility complex (MHC) on their cell surface. 
GM-CSF is used as an adjuvant co-stimulant for func-
tional maturation of the dendritic cells in order for them 
to activate specific CTLs. These specific CTLs are then 
activated themselves and can replicate to form a reservoir 
of CTLs against PAP. They CTLs are then used to form 
the sipuleucel-T vaccine, which is administered to the 
patient. Each vaccine preparation is patient-individual-
ized, i.e. each vaccine is autologous to the patient and thus 
avoids human leukocyte antigen (HLA) mismatching. A 
phase III trial (IMPACT) randomized 512 patients with 
asymptomatic or minimally symptomatic metastatic 
castrate-resistant prostate cancer (CRPC) in a 2:1 fashion, 
to receive either sipuleucel-T or placebo. The IMPACT 
trial was successful in demonstrating prolonged overall 
survival rates for patients with mCRPC vaccinated with 
sipuleucel-T compared to a placebo/control group, al-
though there were no significant differences between the 
two groups in time to cancer progression. A 4.1 month 
improvement in median survival was achieved: 25.8 
months in patients treated with sipuleucel-T versus 21.7 
months in the control patients arm (a 22% relative reduc-
tion in risk of death, hazard ratio 0.78, 95% confidence 
interval 0.61–0.98 P=0.03). Adverse events were more 
prevalent in the sipuleucel-T–treated group, but they were 
generally mild and flulike in nature (24, 25).
In comparison with the above mentioned ACT and 
CARs immunotherapy approach, the technology to gen-
erate in vitro autologous activated dendritic cells and ac-
tivated CTLs is relatively less complex so this approach 
may have a wider applicability for other tumor types. Re-
garding the clinical indication for the Sipuleucel-T ap-
plication in practice, it is in the meantime becoming an 
indication more “squeezed”, because there are now new 
options for additional prostate hormonal manipulations. 
For example, with the abiraterone acetate or enzaluta-
mide, both in the form of tablets in chemotherapy-naive 
patients having no or minimal symptoms (24, 25, 36, 37).
CheCkpOINT blOCkADe
Another novel and perspective immunotherapeutic ap-
proach is immune checkpoint blockade. It has emerged 
as one of the most clinically promising strategies. This 
strategy is based on the nonspecific immune activation 
of T lymphocytes in cancer patients which can be 
achieved by monoclonal antibodies that inhibit co-inhib-
itory signaling pathways. Physiologically, the amplitude 
and duration of T-cell response is regulated by a balance 
between co-stimulatory and co-inhibitory signals (that is, 
immune checkpoints). Through these functionally op-
posite signaling pathways, immune homeostasis and avoid-
ance of immune over-activation (autoimmunity) is main-
tained. The antibodies that block immune checkpoints do 
not target tumor cells directly, but instead target lympho-
cyte receptors for inhibitory signals or their ligands. By 
blocking the T cell receptors for the inhibitory signals or 
inhibitory ligand molecules for these receptors on other 
cells (for example, on antigen presenting cells or on normal 
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and tumor cells), nonspecific (over)activation of T-lympho-
cytes can be obtained, which may also evoke the endoge-
nous antitumor activity. In cancer, inhibitory pathways 
seems to be important in the tumor microenvironment and 
draining lymph nodes and might lead to a state of T-cell 
anergy, thereby allowing tumor to escape from immune 
surveillance, and unchecked tumor growth (34–39).
Cytotoxic T‑lymphocyte associated antigen 4 (CTLA-
4; also known as CD152) and programmed death-1 anti-
gen (PD-1; also known as CD279) were the first two im-
mune checkpoints to be evaluated extensively in the 
setting of clinical cancer immunotherapy. They differ in 
the manner and level at which they negatively regulate 
the immune system. Inhibitory pathway CTLA-4 regu-
lates T-lymphocytes at the level of initial activation, while 
the PD-1 regulates immunity at multiple phases of the 
immune response, including exerting its effect on effector 
T-lymphocyte activity in the peripheral tissues. In the 
priming phase, antigen-presenting cells present antigens 
to the T-cell. Two signals are required to initiate a T-cell 
response. CTLA-4 is upregulated after T-cell activation 
and inhibits the T-cell response set in motion. Anti-CT-
LA-4 antibodies bind to CTLA-4, turning off the “in-
hibitory signal”, thus resulting in an enhancement of T-
cell function. In the effector phase, the PD-1 inhibitory 
receptor is expressed by the T-cell and, when it is engaged 
by its ligands PD-L1 and PD-L2, it serves to inhibit the 
T-cell response. Anti-PD-1 antibodies bind to PD-1, turn-
ing off the “inhibitory signal” in the peripheral tissues and 
enhancing T-cell function. PD-1/PD-L1 interactions are 
complex, and this interaction is also involved in the prim-
ing phase. In addition to its activity in cancer immuno-
therapy, PD-1 has been shown to play a role in allergy, 
autoimmunity, infectious disease, and transplantation 
immunity. PD-1 is highly expressed on tumor-infiltrating 
lymphocytes (TILs) in the effector phase and serves to 
inhibit T-lymphocyte activity during chronic antigen ex-
Figure 1. Simplified schematic representation of  CTLA-4 and PD-1 immune checkpoints. In the priming phase, antigen-presenting cells (APC) 
present antigens to the T-cells. Antigen (short peptide) is presented in the context of the major histocompatibility complex (MHC) class I or class 
II molecules. It is recognized  by the T-cell receptor complex composed of  (TCR) heterodimer protein chains, cluster of differentiain 3 (CD3) 
molecules nad T-cell co-receptor molecules CD8 or CD4, respectively. For T-cells to become fully activated second signal is required. This second 
signal, the „co-stimulatory“ signal, is antigen nonspecific and is provided by the interaction between co-stimulatory molecules expressed on the 
membrane of APC and the T-cell. Co-stimulatory signals are provided by binding of the CD28 receptor on the T-cell surface to its ligand B7-1 
or B7-2 on the APC.  These interactions enhance stimulation of the T-cell, whereas failure of this event results in T-cell anergy (non-activating 
event). As a regulatory mechanism, cytotoxic T-lymphocyte antigen-4 (CTLA-4) is upregulated after T-cell activation and inhibits the T-cell 
response. Binding of CTLA-4 to B7-1 or B7-2 acts as a suppressor response. This step acts as a checkpoint in the immune response cascade and 
prevents adverse and harmful immune activities of T-cells. Anti-CTLA-4 antibodies bind to CTLA-4, turning off the „inhibitory signal“, thus 
resulting in an enhancement of T-cell function. In the effector phase, the programmed cell death-1 (PD-1) inhibitory receptor is expressed by the 
T-cell and, when it is engaged by its ligands PD-L1 and PD-L2, it serves to inhibit the T-cell response. Anti-PD-1 or anti-PD-L1 antibodies 
bind to PD-1 or PD-L1, respectively, turning off the „inhibitory signal“ in the peripheral tissues and enhancing T-cell function. PD-1/PD-L1 
interactions are complex, and this interaction is also involved in the priming phase.
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posure when it is engaged by its ligands. In peripheral 
tissues, tumor cells and other cells in the tumor microen-
vironment may express PD-1 ligands, which may protect 
the tumor cells from immune destruction. Two PD-1 li-
gands are known: PD-L1 (also known as B7-H1 or 
CD274) and PD-L2 (also known as B7-DC or CD273). 
PD-1 ligands are also expressed on different types of tu-
mors. PD-L1 is most commonly expressed on solid tu-
mors, including melanoma, ovarian, lung, and renal car-
cinomas. PD-L2 has been reported to be upregulated in 
different types of lymphoma (34–39).
Several immune checkpoint antibodies are currently 
in clinical trials, with promising results including high 
objective durable response rates (ORR) and a favorable 
side effect profile. These immune checkpoint antibodies 
seems to be clinically active in a variety of malignancies, 
including those not traditionally classified as immuno-
genic, such as non-small-cell lung cancer (NSCLC). En-
couraging clinical results, even with improved survival, 
such as in patients with metastatic melanoma, have been 
obtained. In addition to ipilimumab (Yervoy), antibodies 
against PD-1 such as nivolumab (Obdivo) and pembroli-
zumab (Keytruda) are also FDA approved for the treat-
ment of advanced melanoma. An ongoing challenge is 
learning how to use these agents to optimize tumor re-
gression while avoiding unacceptable toxicity due to en-
hanced autoreactivity of T cells to benign cells. For ex-
ample, the most common adverse events (immune related 
adverse events, irAE’s) following ipilimumab include pru-
ritus, rash, diarrhea, hepatotoxicity, endocrinopathies and 
uveitis. Similar irAE’s have been described with anti-PD-1 
agents including also fatigue and pneumonitis (several 
cases of unfortunately fatal pneumonitis were reported). 
Toxicities may vary across tumor types, depending prob-
ably on antigen expression and recognition and on inten-
sity of the autoreactivity. Treatment algorithms of irAE’s 
include measures such as early treatment with supportive 
care and immunosuppressive medications (for example, 
diet and hydrations recommendations, loperamide, cor-
ticosteroids) (34–40).
CONClUsION
In conclusion, it seems that the recent ongoing clinical 
studies with the ACT, vaccine Sipuleucel-T and with the 
immune check-point activation modulation are demon-
strating, after decades of disappointing immunotherapy 
trials, that the patient’s immune system can be used ef-
fectively in a clinical setting against autologous tumor 
cells. The field of cancer immunotherapy has in fact a long 
history of development and of various experimental ap-
proaches and strategies with mixed results. Because of 
these mixed results, a doubt existed for many years as to 
whether the immune system is capable of eliminating 
autologous cancer. All this, indirectly, indicates that the 
interplay between immunity and cancer is complex. It has 
also become obvious over these many years of research 
that the immune system is able not only to suppress tumor 
growth by destroying cancer cells or inhibiting their out-
growth but also under certain conditions to promote tu-
mor progression either by selecting tumor cells that are 
more fit to survive in an immunocompetent host or by 
establishing conditions within the tumor microenviron-
ment that facilitate tumor outgrowth (“cancer immu-
noediting”). Moreover, a chronic inflammatory microen-
vironment composed of various immune cells 
(macrophages, myeloid-derived suppressor cell, T-regula-
tory cells) within the tumor, and also some cytokines and 
metabolic product can cause T cell dysfunction. Over the 
past two to three decades, however, cancer immunother-
apy has been undergoing a remarkable transition in ef-
fectiveness due to the advances in our understanding of 
the immune system, in the translation of this into the 
clinical practice and also due to the development of nov-
el technologies and immunotherapeutic agents. Still, 
many key questions remain. It is to be expected that more 
relevant and clinically applicable strategies for the identi-
fication of possibly responding patients and assay for the 
immune monitoring of patients undergoing cancer im-
munotherapy will also be tested and developed concomi-
tantly (1, 2, 20, 22, 23, 34, 36, 40).
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